The direct offering by BioXcel Therapeutics is likely to have a short-term negative impact on its stock price due to the dilutive effect of issuing additional shares. However, the capital raised is crucial for the company's continued development of transformative medicines, indicating a potential for long-term growth. The immediate reaction might be negative due to dilution concerns, but the funds are essential for future projects.